A prospective, single-center study of Neoadjuvant chemotherapy with modified FOLFOX6 and Bevacizumab in patients with Potentially Curable Bilobar Liver Metastases from Colorectal Cancer

Trial Profile

A prospective, single-center study of Neoadjuvant chemotherapy with modified FOLFOX6 and Bevacizumab in patients with Potentially Curable Bilobar Liver Metastases from Colorectal Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Dec 2016 New trial record
    • 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top